All In Biotech

Drug Trial Radar · NCT07588568

A Trial of Upadacitinib for Non-responsive Eosinophilic Esophagitis

A Trial of Upadacitinib for Non-responsive Eosinophilic Esophagitis (ATUNE)

Last checked: Nov 20, 2026Latest source record: Oct 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

52

Planned (sponsor's estimate)

Start

Sep 30, 2026

Primary completion

Feb 2030

Study completion Jun 2030

Sponsor

Lead sponsor
University of North Carolina, Chapel HillAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); AbbVie; University of California, San Diego; La Jolla Institute for Immunology; Duke University
First posted
May 15, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Crossover
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this study is to find out if a medication called upadacitinib can help treat a condition called Eosinophilic Esophagitis (EoE). The main question it aims to answer are: \- Does upadacitinib in addition to topical corticosteroids help reduce EoE disease activity? Participants will: * Take upadacitinib or placebo every day for 12 weeks, followed by 12 weeks of upadacitinib * Fill out surveys and answer health questions * Visit the clinic every 4 weeks for checkups and tests

Conditions

  • EoE
  • Eosinophilic Esophagitis
  • Eosinophilic Esophagitis (EoE)

Interventions

  • Upadacitinib 30mg DoseDrug

    Upadacitinib 30mg oral tablet. Participants randomly assigned to receive upadacitinib will take upadacitinib 30mg daily throughout the study. Participants randomly assigned to receive placebo will receive upadacitinib for 12 weeks after completing the 12 week blinded treatment period.

  • Upadacitinib Matching PlaceboOther

    Oral tablet matching in size, shape, color, and taste to the study intervention (upadacitinib). Participants randomly assigned to receive placebo will receive upadacitinib matching placebo for 12 weeks, followed by a 12 week open label treatment period where all participants will receive upadacitinib 30mg.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Peak eosinophil count (measured in eos/hpf) after 12-weeks of treatmentTime frame: At 12-weeks post-treatment

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • University of North Carolina at Chapel Hill

    Chapel Hill, North Carolina · Recruiting

  • Duke University

    Durham, North Carolina · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.